Preferred Dosing for Adults with ADHD
For adults with ADHD, amphetamines should be titrated up to approximately 50 mg/day where efficacy plateaus, while avoiding routine escalation beyond FDA-licensed maximum doses as this provides no additional benefit and worsens tolerability. 1
Medication-Specific Dosing Recommendations
Amphetamines (First-Line)
The most recent and comprehensive dose-effect network meta-analysis from 2026 demonstrates that:
- Efficacy plateaus above approximately 50 mg/day in adults 1
- Start with 2.5-5 mg and titrate upward in 5-10 mg weekly increments until symptoms are controlled 2
- Maximum daily doses typically reach 40 mg for dexamphetamine/mixed amphetamine salts, though some adults may require up to 0.9 mg/kg or 40 mg total daily 2
- No evidence supports exceeding FDA-licensed maximum doses at the population level, and such escalation typically reduces tolerability 1
Methylphenidate (First-Line Alternative)
- Start with 5 mg doses 2
- Titrate in 5-10 mg weekly increments 2
- Maximum daily doses generally 60 mg, though some adults may require up to 1.0 mg/kg or 65 mg 2
- Long-acting formulations (12-hour duration) permit once-daily dosing and are preferred 3
Lisdexamfetamine (First-Line Alternative)
- Prodrug with 12-hour duration and minimal abuse potential 3
- Recommended as first-line alongside methylphenidate 3
Atomoxetine (Second-Line)
- Target dose: 80 mg/day (can be given once daily or divided twice daily) 4
- Once-daily dosing at 80 mg is as effective as 40 mg twice daily, though twice-daily dosing may reduce nausea (16.4% vs 32.4%) 4
- Real-world data shows 36.6% of adults are suboptimally dosed (mean dose 68.5 mg/day), highlighting the importance of adequate titration 5
Critical Dosing Principles
Avoid therapeutic inertia: The 2026 Lancet Psychiatry guideline explicitly challenges accepting suboptimal response without dose titration 1. Clinicians should:
- Titrate upward from minimal doses when symptoms remain insufficiently controlled 1
- Avoid subtherapeutic dosing, which is common and leads to reduced clinical benefits 1
Avoid uncritical dose escalation:
- Exceeding FDA-licensed maximum doses provides no additional efficacy at the population level 1
- Higher-than-licensed doses are associated with reduced tolerability 1
- If maximum recommended doses fail, consider changing medications or adding psychosocial interventions rather than further dose increases 2
Titration Algorithm
- Start low: Begin with 2.5-5 mg amphetamine or 5 mg methylphenidate
- Titrate weekly: Increase by 5-10 mg increments for methylphenidate or 2.5-5 mg for amphetamines 2
- Monitor systematically: Assess target symptoms weekly during titration via patient self-report 2
- Identify plateau: For amphetamines, efficacy plateaus around 50 mg/day in adults 1
- Document higher doses: If exceeding typical maximums (65 mg methylphenidate, 40 mg amphetamine), clearly document that symptoms could not be controlled at lower doses and monitor for tolerance 2
Monitoring Requirements
- Weekly contact during titration phase (2-4 weeks) 2
- Monthly visits until symptoms stabilized 2
- Assess for cardiovascular effects (blood pressure, heart rate increases) 6
- Monitor for psychiatric adverse effects (mood disturbances, anxiety, psychosis) 7
- Evaluate appetite changes and weight 2
Common Pitfalls
Suboptimal dosing is prevalent: Real-world evidence shows many adults receive inadequate doses, particularly with atomoxetine where 36.6% are underdosed 5. This represents a critical quality gap.
Individual variation exists: While population-level data shows no benefit beyond licensed maximums, some individuals may require higher doses 1. In these rare cases, carefully weigh potential benefits against safety concerns from long-term observational studies 1.
Duration matters: Adults require more frequent dosing to cover longer days compared to children, which may result in higher total daily doses 2. Long-acting formulations (10-12 hours) are preferred to reduce dosing frequency 3, 6.